SEC Form 4 · accession 0001610717-26-000216
Revolution Medicines, Inc. · RVMD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Margaret A Horn
Officer — Chief Operating Officer
Period of report
Jun 11, 2026
Accepted (ET)
Jun 15, 2026 · 4:05 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001628171
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Jun 11, 2026 | M | 1,094 | $42.45 | A | 159,316 | D | |
| Common StockF2 | Jun 11, 2026 | M | 8,906 | $40.74 | A | 168,222 | D | |
| Common StockF4,F2 | Jun 11, 2026 | S | 1,315 | $144.2793 | D | 166,907 | D | |
| Common StockF5,F2 | Jun 11, 2026 | S | 885 | $145.1495 | D | 166,022 | D | |
| Common StockF6,F2 | Jun 11, 2026 | S | 700 | $146.0371 | D | 165,322 | D | |
| Common StockF7,F2 | Jun 11, 2026 | S | 500 | $147.272 | D | 164,822 | D | |
| Common StockF8,F2 | Jun 11, 2026 | S | 1,800 | $148.7231 | D | 163,022 | D | |
| Common StockF9,F2 | Jun 11, 2026 | S | 4,600 | $149.6429 | D | 158,422 | D | |
| Common StockF2 | Jun 11, 2026 | S | 200 | $150.17 | D | 158,222 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $42.45 | Jun 11, 2026 | M | 1,094 | D | Aug 9, 2023 | Mar 3, 2031 | Common Stock | 1,094 | 0 | D |
| Stock Option (Right to Buy)F10 | $40.74 | Jun 11, 2026 | M | 8,906 | D | — | Feb 28, 2035 | Common Stock | 8,906 | 91,194 | D |
Explanation of responses
- F1Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026.
- F10One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2025 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.
- F2Includes 73,050 restricted stock units.
- F3Includes 652 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2026.
- F4This transaction was executed in multiple trades in prices ranging from $143.78 to $144.76, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F5This transaction was executed in multiple trades in prices ranging from $144.79 to $145.61, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F6This transaction was executed in multiple trades in prices ranging from $145.88 to $146.16, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F7This transaction was executed in multiple trades in prices ranging from $147.06 to $147.41, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F8This transaction was executed in multiple trades in prices ranging from $148.14 to $149.08, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F9This transaction was executed in multiple trades in prices ranging from $149.17 to $150.15, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.